Get a deeper insight into the potential performance of Idexx (IDXX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water gains.
IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.
IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.
NVIDIA, IDXX and Microsoft shine on ESG metrics, fueling investor interest with strong returns and ambitious 2030 goals.
Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.